Survival outcomes associated with IC after HMA and VEN. (A) OS measured relative to the start of IC for all patients receiving IC after HMA/VEN. (B) OS relative to the start of IC stratified based on prior response to HMA/VEN. (C) OS relative to the start of IC stratified by the line of therapy in which HMA/VEN was used. (D) OS relative to the start of IC stratified based on age over or under 65 years. HR, hazard ratio.